Navigation Links
Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Date:4/22/2008

statistically significant 50 percent reduction in late loss compared to

TAXUS (mean, 0.14 mm for XIENCE V vs. 0.28 mm for TAXUS).

-- Statistical non-inferiority to TAXUS in the major secondary

(co-primary) endpoint of target vessel failure (TVF) at nine months.

XIENCE V demonstrated an observed 20 percent reduction in TVF compared

to TAXUS (7.2 percent for XIENCE V vs. 9.0 percent for TAXUS). TVF is a

composite clinical measure of safety and efficacy outcomes defined as

cardiac death, heart attack (myocardial infarction or MI) or target

vessel revascularization (TVR).

-- An observed 43 percent reduction in the pre-specified secondary

endpoint of major adverse cardiac events (MACE) at nine months

(4.6 percent for XIENCE V vs. 8.1 percent for TAXUS) and an observed

42 percent reduction in MACE at one year (6.0 percent for XIENCE V vs.

10.3 percent for TAXUS) compared to TAXUS. MACE is an important

composite clinical measure of safety and efficacy outcomes for

patients, defined as cardiac death, heart attack (MI), or

ischemia-driven target lesion revascularization (TLR driven by lack of

blood supply).

"The low rate of MACE seen with XIENCE V in the SPIRIT III trial can be directly attributed to fewer patients experiencing heart attacks or re-treatment, and is consistent with data from previous trials," said Charles Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs and chief medical officer, Abbott Vascular. "Superior efficacy combined with increased flexibility and deliverability reinforce that XIENCE V is a significant advancement in stent technology that will be a welcome addition to the field of interventional cardiology."

Additional Results from SPIRIT III

There were no significant differences between XIENCE V and TAXUS in the rates of stent thrombosis either early (less than or
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
2. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
3. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
4. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
5. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
8. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
9. Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimers Disease Announced
10. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study
11. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... VANCOUVER , July 30, 2015  OncoGenex Pharmaceuticals, ... will report its second quarter 2015 financial results on ... conference call and live webcast at 4:30 p.m. Eastern ... development programs and a general corporate update. ... Investor Relations page of the OncoGenex website at ...
(Date:7/30/2015)... 30, 2015  Cleveland Clinic President Wael Barsoum ... last month that industry is compelled to adopt declining ... the efficiencies—and develop the transformational innovations -- required to ... were preceded by Doug Kohrs , past President ... who stressed that industry must add "episode of care," ...
(Date:7/30/2015)...  Medimetriks Pharmaceuticals, Inc. announced today that its ... study for Ozenoxacin, a novel bactericidal non-fluorinated quinolone ... U.S. rights to Ozenoxacin 1% cream.  ... with an emphasis on U.S. patients, involved 412 ... older with a clinical diagnosis of bullous or ...
Breaking Medicine Technology:Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... proud to announce that their latest designer handbag line will be named for ... an Internet sensation as the first globally recognized model with Down syndrome, gracing ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... has announced plans to release a newly redesigned website at Healthpointe.net. The new ... enhanced user experience. , The redesign serves to provide smoother interactions between ...
(Date:7/31/2015)... ... July 31, 2015 , ... ZH Healthcare announces a ... , What is HITaaS? Health IT as a Service (HITaaS) is a Healthcare dedicated ... a service (SaaS). , HITaaS manages all aspects of infrastructure, security, ...
(Date:7/31/2015)... ... July 31, 2015 , ... EB ... and Hospital Medicine Practice, is pleased to announce that it has partnered with ... format available on iPhones, iPads, and Android smartphones and tablets. , “The ...
(Date:7/31/2015)... ... ... The Radiology Business Management Association’s 2015 Fall Educational Conference ... Care: A View From Capitol Hill” on Sunday, Sept. 27, 2015, in Austin, Tex. ... has a special understanding of the real world impact of health care policy issues,” ...
Breaking Medicine News(10 mins):Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:Healthpointe Announces Newly Redesigned Website 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 2Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 3
... new vaccine called the TAT vaccine has been developed in ... date. And more importantly it has had a 71% success ... for human testing and this may be the brightest hope ... of the Department of Virology at Italy’s National Health Institute ...
... social neglect and being unwanted even by near and dear ... like the other people - wherever they want and whenever ... passengers. Others are just indifferent. Leaving the ethical issues aside, ... of, many reasons. Primarily the physicians of these patients do ...
... The outgoing U.S. president Bill Clinton will be remembered as ... by becoming the first American president in history to be ... to win at the senate did he save himself and ... of many burning controversies throughout his term and his mid ...
... pregnancy can lead to increased risk of heart problems ... environment contribute to several aspects of cardiovascular risks in ... ,People whose mothers starved during the first 13 ... their adult life, Starvation during mid or late pregnancy ...
... cancer is pancreatic cancer, though it isn’t very common. Globally ... is some hope for the unfortunate victims. A new vaccine ... it has increased the survival rates in many. ,Vaccines ... In cancer, however, they are used along with other therapies ...
... new research into how our immunity works says stress reduces ... long we have agreed that stress is bad for our ... is sure to cause a lot of concern. , ... claming many victims every day, the new buzzword is immunity ...
Cached Medicine News:
An enzyme linked immunoassay (ELISA) for the detection and semiquantitationof IgG and IgM antibodies to 2-GP1, as an aid in assessingthe risk of thrombosis in patients with Systemic Lupus Erythematos...
An enzyme linked immunoassay (ELISA) for the detection and semiquantitation of IgG, IgA or IgM anticardiolipin antibodies, as an aid in assessing the risk of thrombosis in individuals with Systemic L...
The ImagingPlanet 70 mm surgical microscope video adapter: superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Zeiss surgical...
The ImagingPlanet 55 mm surgical microscope video adapter: superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Leica surgical ...
Medicine Products: